Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Last Updated: January 26, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Thymalfasin

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Thymalfasin?

Thymalfasin is an investigational drug.

There have been 17 clinical trials for Thymalfasin. The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2015.

The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, and Hepatitis. The leading clinical trial sponsors are SciClone Pharmaceuticals, Zhejiang Provincial People’s Hospital, and Sun Yat-sen University.

There are seven hundred and fifty-one US patents protecting this investigational drug and eight international patents.

Recent Clinical Trials for Thymalfasin
Efficacy and Safety of Combination Therapy of Thymalfasin and Entecavir in HBeAg-positive ETV-experienced PatientsWen-hong ZhangPhase 4
Clinical Studies by Using Accelerated PDX Model to Screen Drugs for Advanced Solid TumorHaining Health-Coming Biotech Co., Ltd.Phase 2
First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care TherapySciClone PharmaceuticalsPhase 1/Phase 2

See all Thymalfasin clinical trials

Clinical Trial Summary for Thymalfasin

Top disease conditions for Thymalfasin
Top clinical trial sponsors for Thymalfasin

See all Thymalfasin clinical trials

US Patents for Thymalfasin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Thymalfasin   Start Trial Method for treating secondary immunodeficiency University of South Florida (Tampa, FL)   Start Trial
Thymalfasin   Start Trial T.alpha.1 .alpha.-tubulin promoter and expression vectors McGill University (Montreal, CA)   Start Trial
Thymalfasin   Start Trial Method of using, process of preparing and composition comprising recombinant herpesvirus vectors University of British Columbia (Vancouver, CA)   Start Trial
Thymalfasin   Start Trial DHA-pharmaceutical agent conjugates of taxanes Neuromedica, Inc. (Conshohocken, PA)   Start Trial
Thymalfasin   Start Trial Taxane compounds and compositions Neuromedica, Inc. (Conshohocken, PA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Thymalfasin

Drugname Country Document Number Estimated Expiration Related US Patent
Thymalfasin Austria 419860 2014-11-17   Start Trial
Thymalfasin Australia 4240096 2014-11-17   Start Trial
Thymalfasin Australia 702770 2014-11-17   Start Trial
Thymalfasin Canada 2205405 2014-11-17   Start Trial
Thymalfasin Germany 69535904 2014-11-17   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.